Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders [Yahoo! Finance]
Virax Biolabs Group Limited - Ordinary Shares (VRAX)
Company Research
Source: Yahoo! Finance
in the Company's current public valuation despite its balance sheet strength, debt-free position, recent financing and operational progress. LONDON April 14, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immunology research and diagnostics, today published a shareholder letter from Chief Executive Officer James Foster and released an updated investor presentation. Together, these materials outline Virax's current strategic and commercial framework and the milestones management believes matter most over the next 90 to 180 days. An investigational ViraxImmune™ kit, part of Virax Biolabs' in-development T-cell immune-profiling platform. ViraxImmune™ is currently in development and is not approved for diagnostic use in any jurisdiction The Company's updated Q2 2026 investor presentation is available at: https://diagnostics.viraxbiolabs.com/virax-biolabs-q2-2026-investor-presentation/ Highl
Show less
Read more
Impact Snapshot
Event Time:
VRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRAX alerts
High impacting Virax Biolabs Group Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
VRAX
News
- Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to ShareholdersPR Newswire
- Virax Biolabs Group (VRAX) had its "sell (e+)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation [TheStreet.com]TheStreet.com
- Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical ValidationPR Newswire
VRAX
Sec Filings
- 4/14/26 - Form 6-K
- 4/10/26 - Form 6-K
- 3/31/26 - Form 3
- VRAX's page on the SEC website